Hepatitis C Virus Envelope Protein E2 Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 36 Published: October 31, 2021 Report Code: GMDGDHC2985TDB

The Hepatitis C Virus Envelope Protein E2 targeted pipeline market research report provides comprehensive information on the Hepatitis C Virus Envelope Protein E2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics development with respective active and dormant or discontinued projects.

What are the key MoA in the Hepatitis C Virus Envelope Protein E2 targeted pipeline market?

The key MoA in the Hepatitis C Virus Envelope Protein E2 targeted pipeline market is Hepatitis C Virus Envelope Protein E2 Inhibitor.

What are the key RoA in the Hepatitis C Virus Envelope Protein E2 targeted pipeline market?

The key RoA in the Hepatitis C Virus Envelope Protein E2 targeted pipeline market are intramuscular and oral. Both intramuscular and oral have the same number of pipeline products in the Hepatitis C Virus Envelope Protein E2 targeted pipeline market.

What are the key molecule types in the Hepatitis C Virus Envelope Protein E2 targeted pipeline market?

The key molecule types in the Hepatitis C Virus Envelope Protein E2 targeted pipeline market are Subunit Vaccine, Monoclonal Antibody, DNA Vaccine, Inactivated Vaccine, and Synthetic Peptide. Subunit vaccine has the highest number of pipeline products.

Hepatitis C Virus Envelope Protein E2 targeted pipeline market, by molecule types

Hepatitis C Virus Envelope Protein E2 targeted pipeline market, by molecule types

For more molecule type insights, download a free sample

Which are the key companies in the Hepatitis C Virus Envelope Protein E2 targeted pipeline market?

The key companies in the Hepatitis C Virus Envelope Protein E2 targeted pipeline market are Ennaid Therapeutics LLC, Integrated BioTherapeutics Inc, Toray Industries Inc, and Uvax Bio LLC.

Market report overview

Key MoA Hepatitis C Virus Envelope Protein E2 Inhibitor
Key RoA Intramuscular and Oral
Key molecule type Subunit Vaccine, Monoclonal Antibody, DNA Vaccine, Inactivated Vaccine, and Synthetic Peptide
Keu companies Ennaid Therapeutics LLC, Integrated BioTherapeutics Inc, Toray Industries Inc, and Uvax Bio LLC

Scope

  • The report provides a snapshot of the global therapeutic landscape for Hepatitis C Virus Envelope Protein E2
  • The report reviews Hepatitis C Virus Envelope Protein E2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hepatitis C Virus Envelope Protein E2 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hepatitis C Virus Envelope Protein E2 targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hepatitis C Virus Envelope Protein E2Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatitis C Virus Envelope Protein E2 development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Players

  • Ennaid Therapeutics LLC

    Integrated BioTherapeutics Inc

    Toray Industries Inc

    Uvax Bio LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepatitis C Virus Envelope Protein E2 – Overview

Hepatitis C Virus Envelope Protein E2 – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Hepatitis C Virus Envelope Protein E2 – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatitis C Virus Envelope Protein E2 – Companies Involved in Therapeutics Development

Ennaid Therapeutics LLC

Integrated BioTherapeutics Inc

Toray Industries Inc

Uvax Bio LLC

Hepatitis C Virus Envelope Protein E2 – Drug Profiles

CIGB-230 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis C (strain H77) vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis C vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis C vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis C vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis C vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Hepatitis C – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit E1 and E2 Glycoprotein for Hepatitis C – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit E1 and E2 Glycoprotein for HCV – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatitis C Virus Envelope Protein E2 – Dormant Products

Hepatitis C Virus Envelope Protein E2 – Discontinued Products

Hepatitis C Virus Envelope Protein E2 – Product Development Milestones

Featured News & Press Releases

Jun 10, 2013: IBT and Stanford Awarded STTR

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Ennaid Therapeutics LLC, 2021

Pipeline by Integrated BioTherapeutics Inc, 2021

Pipeline by Toray Industries Inc, 2021

Pipeline by Uvax Bio LLC, 2021

Dormant Projects, 2021

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

Frequently Asked Questions

$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.